NA
Natural Capsules Ltd (NATCAPSUQ)
₹126.19
Mkt cap
₹132 Cr
P/E ratio
—
P/B
0.60
Div yield
0.00%
ROE
−9.45%
ROCE
−4.58%
EPS (TTM)
—
Book value
₹209
52W range
126–234
Sector
Healthcare
Price history
Previous close
Incorporated in 1993, Natural Capsules manufactures Capsules and Steroidal APIs and their Intermediates and Derivatives [1]
NSE NATCAPSUQBSE 524654
Health check
Cautious
ProfitabilityWeak
GrowthModerate
TechnicalsBearish
52-week range
−46.07% from high₹126
₹1260.00% from low₹234
Current
₹126.19
Prev close
₹132.83
Day
−5.00%
Price performance
1D
−5.00%
1W
−17.05%
1M
−16.06%
3M
−16.65%
6M
−16.83%
1Y
−38.10%
YTD
−36.16%
Financials
Revenue, profit & margin
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 37.52 | 39.98 | 40.22 | 39.18 | 41.22 | 43.83 | 44.97 | 45.20 | 45.80 | 37.75 | 58.45 | 48.71 | 51.15 | |
| YoY Sales growth | -16.73% | -12.13% | +6.91% | +3.93% | +9.86% | +9.63% | +11.81% | +15.36% | +11.11% | -13.87% | +29.98% | +7.77% | +11.68% | |
| Expenses | 32.40 | 35.26 | 36.11 | 34.81 | 36.72 | 39.56 | 40.58 | 44.88 | 46.69 | 40.07 | 57.12 | 47.59 | 48.14 | |
| Operating Profit | 5.12 | 4.72 | 4.11 | 4.37 | 4.50 | 4.27 | 4.39 | 0.32 | -0.89 | -2.32 | 1.33 | 1.12 | 3.01 | |
| OPM % | 13.65% | 11.81% | 10.22% | 11.15% | 10.92% | 9.74% | 9.76% | 0.71% | -1.94% | -6.15% | 2.28% | 2.30% | 5.88% | |
| Other Income | 0.35 | 0.50 | 0.92 | 0.18 | 0.11 | 0.11 | 0.30 | 0.36 | 0.16 | 0.45 | 0.76 | 0.17 | 0.19 | |
| Interest | 1.16 | 1.24 | 1.40 | 1.49 | 1.65 | 1.54 | 1.64 | 2.53 | 2.68 | 2.85 | 2.89 | 2.79 | 2.91 | |
| Depreciation | 2.17 | 2.19 | 2.20 | 2.28 | 2.35 | 2.33 | 2.16 | 4.21 | 4.29 | 4.36 | 4.28 | 4.33 | 4.87 | |
| Profit before tax | 2.14 | 1.79 | 1.43 | 0.78 | 0.61 | 0.51 | 0.89 | -6.06 | -7.70 | -9.08 | -5.08 | -5.83 | -4.58 | |
| Tax % | 27.10% | 32.96% | 32.17% | 21.79% | 201.64% | 78.43% | 41.57% | -8.09% | -9.09% | -21.70% | -1.97% | -1.54% | -7.86% | |
| Net Profit | 1.56 | 1.21 | 0.97 | 0.60 | -0.61 | 0.11 | 0.52 | -5.58 | -6.99 | -7.12 | -4.98 | -5.74 | -4.23 | |
| EPS in Rs | 1.68 | 1.30 | 1.04 | 0.64 | -0.60 | 0.11 | 0.35 | -5.40 | -3.82 | -4.77 | -3.32 | -2.60 | -1.17 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202650.92%Promoter
Promoters50.92%
FIIs0.08%0.08
DIIs0.00%
Public48.99%0.10
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,884.90 | 36.70 | 4,51,538 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,180.50 | 86.86 | 2,96,807 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,689.50 | 82.07 | 1,78,180 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,294.60 | 92.69 | 1,24,195 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,200.00 | 26.48 | 1,19,990 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,390.20 | 41.56 | 1,16,360 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,415.00 | 36.88 | 1,14,518 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Natural Capsules | ₹126.19 | — | 132 | 0.00% | −4 | +69.11% | 51 | +11.68% | −4.58% |
| Median: 160 Co. | ₹432.20 | 32.47 | 1,987 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Concall transcripts32
PPTNov 2026RECNov 2026PPTAug 2026TranscriptJun 2026PPTJun 2026RECJun 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025PPTAug 2025TranscriptJun 2025TranscriptJun 2025PPTJun 2025RECJun 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024RECNov 2024TranscriptMay 2024PPTMay 2024PPTFeb 2024TranscriptNov 2023PPTNov 2023PPTAug 2023
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 19 Nov - Audio recording of November 19, 2026 conference call uploaded on company website.Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 16 NovAnnouncement under Regulation 30 (LODR)-Press Release / Media Release 15 Nov - Natural Capsules reports Q2 FY27 revenue of ₹51.15 crore and H1 revenue of ₹99.86 crore.Announcement under Regulation 30 (LODR)-Investor Presentation 15 Nov - Copy of Investor Presentation in connection with Q2 Financial Results.Announcement under Regulation 30 (LODR)-Newspaper Publication 15 Nov - Unaudited Financial Results for Quarter and Half Yearly ended September 20, 2026, has been published in Business Line (English Newspaper) and Sanjevani (Kannada Newspaper).






